Factors regulating the progression of hypertensive nephrosclerosis

Contributions to Nephrology

Volumn 139, Issue , 2003, Pages 173-186

  Razzaque, Mohammed S ^a,c   Azouz, Abdallah ^b   Shinagawa, Tatsuo ^d   Taguchi, Takashi ^c  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NAGASAKI UNIVERSITY   (Japan)

^d Kawatana National Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DISEASE MODEL; HUMAN; KIDNEY; NEPHROSCLEROSIS; PATHOLOGY; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; HYPERTENSION, RENAL; KIDNEY; KIDNEY FAILURE, CHRONIC; NEPHROSCLEROSIS;

EID: 0141922635     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071743     Document Type: Article

References (65)

1. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.
2. US Renal Data System; in USRDS 1991 Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1991.
3. US Renal Data System: Annual Data Report 1994. Incidence and causes of treated ESRD. Am J Kidney Dis 1994;24(suppl 2):48-56.
4. Brunner FP, Selwood NH, on behalf of the EDTA Registration Committee: Profile of patients on RRT in Europe and death rates groups. Kidney Int 1992;42(suppl 38):4-15.
5. Nakai S, et al: The current state of chronic dialysis treatment in Japan. Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan. J Jpn Soc Dial Ther 2002;35:1155-1184.
6. Luke RG: Essential hypertension: A renal disease. A review and update of the evidence. Hypertension 1993;21:380-390.
7. Dustan HP: Growth factors and racial differences in severity of hypertension and renal diseases. Lancet 1992;339:1339-1340.
8. Teio KK: Angiotensin-converting enzyme genotypes and disease. BMJ 1995;311:76-77.
9. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH: The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995;95:948-953.
10. Rutledge DR, Kubilis P, Browe CS, Ross EA: Polymorphism of the angiotensin I converting enzyme gene in essential hypertensive patients. Biochem Mol Biol Int 1995;35:661-668.
11. Duru K, Farrow S, Wang JM, Lockette W, Kurtz T: Frequency of a deletion polymorphism in the gene for angiotensin-converting enzyme is increased in African-Americans with hypertension. Am J Hypertens 1994;7:759-762.
12. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Kanai T, Miyazaki Y, Kawaguchi Y, Kubo H, Nagasawa R, Ichikawa I, Sakai O: Role of the deletion polymorphism of the angiotensinconverting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96:2162-2169.
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
14. Ueda S, Elliott HL, Morton JJ, Connell JMC: Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995;25:1266-1269.
15. Takebayashi S, Kiyoshi Y, Hisano S, Uesugi N, Sasatomi Y, Meng J, Sakata N: Benign nephrosclerosis: Incidence, morphology and prognosis. Clin Nephrol 2001;55:349-356.
16. Vaziri ND, Wang XQ, Oveisi F, Rad B: Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000;36:142-146.
17. Mizutani K, Ikeda K, Nishikata T, Yamori Y: Phytoestrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Hypertens 2000;18:1833-1840.
18. Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, Pourdjabbar A, Jasmin JF, Sarrazin JF, Liu P, Adam A, Butany J, Rouleau JL: Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 2002;105:2549-2555.
19. 1 expression and phenotypic modulation in the kidney of hypertensive rats. Hypertension 1995;26:199-207.
20. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC: Monocyte infiltration and adhesion molecules in a rat model of high human rennin hypertension. Hypertension 1999;33:389-395.
21. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmilz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H: Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension 1999;33:212-218.
22. Suda T, Osajima A, Tamura M, Kato H, Iwamoto M, Ota T, Kanegae K, Tanaka H, Anai H, Kabashima N, Okazaki M, Nakashima Y: Pressure-induced expression of monocyte chemoattractant protein-1 through activation of MAP kinase. Kidney Int 2000;60:1705-1715.
23. Rovin BH, Wilmer WA, Danne M, Dickerson JA, Dixon CL, Lu L: The mitogen-activated protein kinase p38 is necessary for interleukin-lβ-induced monocyte chemoattractant protein-1 expression by human mesangial cells. Cytokine 1999;11:118-126.
24. Hilgers KF, Hartner A, Porst M, Veelken R, Mann JF: Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: Relation to kidney inflammation. Circulation 2001;104:1436-1440.
25. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC: Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 1995;48:753-760.
26. Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, Metz CN, Bucala R, Atkins RC: Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 2000;57:499-509.
27. Razzaque MS, Foster CS, Ahmed AR: Role of enhanced expression of m-CSF in conjunctiva affected by cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2002;43:2977-2983.
28. Border WA, Noble NA: Cytokines in kidney disease: The role of transforming growth factor-β. Am J Kidney Dis 1993;22:105-113.
29. Barnard JA, Lyons RM, Moses HL: The cell biology of transforming growth factor-β. Biochim Biophys Acta 1990;1032:79-87.
30. Tamaki K, Okuda S: Role of TGF-β in the progression of renal fibrosis; Razzaque MS, Taguchi T (eds): Renal Fibrosis. Contrib Nephrol. Basel, Karger 2003, Vol 139, pp 44-65.
31. 1. Nature 1990;346: 371-374.
32. 1 in tubulointerstitial damage in hypertensive nephrosclerosis: An immunohistochemical study. J Int Med Res 1996;24:199-208.
33. Razzaque MS, Cheng M, Horita Y, Nishihara M, Harada T, Taguchi T: Immunohistochemical analysis of type III and IV collagens in tubulointerstitial damage in human benign nephrosclerosis. J Int Med Res 1995;23:480-486.
34. Razzaque MS, Koji T, Kawano H, Harada T, Nakane PK, Taguchi T: Glomerular expression of type III and type IV collagens in benign nephrosclerosis: Immunohistochemical and in situ hybridization study. Pathol Res Pract 1994;190:493-499.
35. 1 in essential hypertension. Am J Hypertens 2002;15:207-211.
36. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ: Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am J Physiol 2002;283:R757-R767.
37. Laviades C, Varo N, Diez J: Transforming growth factor-β in hypertensives with cardiorenal damage. Hypertension 2000;36:517-522.
38. Cerwenka A, Swain SL: TGF-βi: Immunosuppressant and viability factor for T lymphocytes. Microbes Infect 1999;1:1291-1296.
39. 1 induction. Immunol Today 1999;20:384-385.
40. Yokoi H, Mukoyama M, Sugawara A, Mori K, Nagae T, Makino H, Suganami T, Yahata K, Fujinaga Y, Tanaka I, Nakao K: Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 2002;282:F933-F942.
41. Razzaque MS, Foster CS, Ahmed AR: Role of connective tissue growth factor in the pathogenesis of conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2003;44:1998-2003.
42. Finckenberg P, Lassila M, Inkinen K, Pere AK, Krogerus L, Lindgren L, Mervaala E, Vapaatalo H, Nurminen ML, Ahonen J: Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation 2001;71:951-958.
43. Razzaque MS, Taguchi T: Collagen-binding heat-shock protein 47 expression in anti-thymocyte serum-induced glomerulonephritis. J Pathol 1997;183:24-29.
44. Razzaque MS, Nazneen A, Taguchi T: Immunolocalization of collagen and collagen-binding heatshock protein 47 in fibrotic lung diseases. Mod Pathol 1998;11:1183-1188.
45. 1 are induced in cicatricial pemphigoid: Possible role(s) in dermal fibrosis. Cytokine 2002;17:311-316.
46. Razzaque MS, Shimokawa I, Nazneen A, Higami Y, Taguchi T: Age-related nephropathy in the Fischer 344 rat is associated with overexpression of collagens and collagen-binding heat-shock protein 47. Cell Tissue Res 1998;293:471-478.
47. 1 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2003;44:1616-1621.
48. Razzaque MS, Hossain MA, Kohno S, Taguchi T: Bleomycin-induced pulmonary fibrosis in rat is associated with increased expression of collagen-binding heat-shock protein 47. Virchows Arch 1998;432:455-460.
49. Razzaque MS, Kumatori A, Harada T, Taguchi T: Coexpression of collagens and collagen-binding heat-shock protein 47 in human diabetic nephropathy and IgA nephropathy. Nephron 1998;80:434-443.
50. Razzaque MS, Taguchi T: The possible role of colligin/HSP47, a collagen-binding protein, in the pathogenesis of human and experimental fibrotic diseases. Histol Histopathol 1999;14:1199-1212.
51. Tikkanen I, Uhlenius N, Tikkanen T, Miettinen A, Tornroth T, Fyhrquist F, Holthofer H: Increased renal expression of cytokines and growth factors induced by DOCA-NaCl treatment in Heymann nephritis. Nephrol Dial Transplant 1995;10:2192-2198.
52. Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju KH, Wang Y, Ebihara A, Nishimatsu H, Moriyama N, Fukuda M, Akimoto Y, Hirano H, Morita H, Kumada M, Yazaki Y, Nagai R, Kimura K: Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med 2002;80:105-116.
53. Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, Barnes PJ, Giaid A: Elevated expression of endothelin-1 and endothel in-converting enzyme-1 in idiopathic pulmonary fibrosis: Possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-193.
54. Park SH, Saleh D, Giaid A, Michel RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156:600-608.
55. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule JC: Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999;99:2185-2191.
56. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, Selman M: Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990;86:1055-1064.
57. 1 or platelet-derived growth factor B gene. Proc Natl Acad Sci USA 1995;92:9570-9574.
58. Dobrian A, Wade SS, Prewitt RL: PDGF-A expression correlates with blood pressure and remodeling in 1K1C hypertensive rat arteries. Am J Physiol 1999;276:H2159-H2167.
59. Kishioka H, Fukuda N, Wen-Yang H, Nakayama M, Watanabe Y, Kanmatsuse K: Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in strokeprone spontaneously hypertensive rats. Am J Hypertens 2001;14:439-145.
60. Yaguchi T, Fukuda Y, Ishizaki M, Yamanaka N: Immunohistochemical and gelatin zymography studies for matrix metalloproteinases in bleomycin-induced pulmonary fibrosis. Pathol Int 1998;48:954-963.
61. Madtes DK, Elston AL, Kaback LA, Clark JG: Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2001;24:599-607.
62. Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A: TIMP-1, -2, -3 and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol 2000;279:L562-L574.
63. Lindsay MM, Maxwell P, Dunn FG: TIMP-1: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-141.
64. Fogo AB: Mechanisms in nephrosclerosis and hypertension-beyond hemodynamics. J Nephrol 2001;4:S63-S69.
65. Loskutoff DJ, Quigley JP: PAI-1, fibrosis and the elusive provisional fibrin matrix. J Clin Invest 2000;106:1441-1443.